The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women

Sponsor
Palm Beach Center for Reproductive Medicine (Other)
Overall Status
Completed
CT.gov ID
NCT01290432
Collaborator
Lo.Li. Pharma, Ltd. (Other)
15
1
1
12
1.3

Study Details

Study Description

Brief Summary

Dr. Roseff and his colleagues are conducting a study to evaluate the effectiveness of a novel substance (Inofolic Plus®) in improving oocyte (egg) parameters in subfertile female patients, as measured through Anti-Mullerian Hormone (AMH) blood levels.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Inofolic Plus
N/A

Detailed Description

Inofolic Plus® contains several nutritional elements including myo-inositol, melatonin, and folic acid. Myo-inositol was found to be helpful in improving egg quality and/or quantity in women with an ovarian abnormality called polycystic ovarian syndrome as well as in women without the disorder undergoing assisted reproduction.

Myo-inositol and folic acid are compounds that belong to the family of B-vitamins. Inositol is normally found in several types of foods. Folic acid has been found to significantly decrease the incidence of certain types of birth defects in women taking sufficient amounts prior to and during pregnancy. Preliminary studies using myo-inositol and folic acid demonstrated improvement in egg quality in-vitro and in-vivo as well as multiple metabolic parameters in women with irregular menstrual cycles and certain types of hormone imbalances.

Melatonin is a potent antioxidant. Folic acid is not classified as an antioxidant but has been reported to have antioxidant-like activity. Antioxidants have been given to infertile men for years to improve egg parameters. Most recently, studies have documented the efficacy of antioxidant treatment on human egg parameters and fertilization rates, especially in the setting of in-vitro fertilization (IVF). Inofolic Plus® contains melatonin and folic acid. Dr. Roseff hypothesizes that Inofolic Plus® may be effective in correcting abnormal egg parameters in women. A woman may have abnormal eggs from being exposed to environmental and workplace toxins that generate oxygen free radicals in her body (known as reactive oxygen species, or ROS). These ROS circulate through the blood stream and can enter the ovaries where eggs are stored. Eggs may be sensitive to ROS, and damage from the ROS may result in poor egg quality or quantity or both. The combination of nutrients and antioxidants in Inofolic Plus® may help to correct these abnormalities. Melatonin is a natural hormone normally found in the brain. This hormone helps regulate sleep/wake cycles. Melatonin levels increase during the evening and remain high during the night. This elevated level of melatonin is thought to induce drowsiness. It is because of this effect that we recommend taking Inofolic Plus® in the late evening near bedtime.

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women
Study Start Date :
Feb 1, 2011
Actual Primary Completion Date :
Feb 1, 2012
Actual Study Completion Date :
Feb 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: Inofolic Plus

Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.

Dietary Supplement: Inofolic Plus
Inofolic Plus contains folic acid and myoinositol and melatonin
Other Names:
  • folic acid, myoinositol, and melatonin in combination
  • Outcome Measures

    Primary Outcome Measures

    1. Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve (AMH Levels) [Three Months]

      Women will receive Infolic Plus nightly for up to 90 days. Baseline AMH blood levels will be analyzed, and AMH titers will be checked monthly thereafter for the 90 day duration of the study.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 42 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Female between 18 - 42 years of age

    • Diagnosed with "Diminished Ovarian Reserve" (DOR)

    Exclusion Criteria:
    • Ongoing history of illicit drug or tobacco use

    • Ovarian surgery within 90 days of signing the consent form

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Palm Beach Center for Reproductive Medicine Wellington Florida United States 33414

    Sponsors and Collaborators

    • Palm Beach Center for Reproductive Medicine
    • Lo.Li. Pharma, Ltd.

    Investigators

    • Principal Investigator: Scott Roseff, MD, Palm Beach Center for Reproductive Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Scott Roseff, MD, Principal Investigator, Palm Beach Center for Reproductive Medicine
    ClinicalTrials.gov Identifier:
    NCT01290432
    Other Study ID Numbers:
    • Roseff-01
    First Posted:
    Feb 7, 2011
    Last Update Posted:
    May 25, 2012
    Last Verified:
    May 1, 2012
    Keywords provided by Scott Roseff, MD, Principal Investigator, Palm Beach Center for Reproductive Medicine
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 25, 2012